166 related articles for article (PubMed ID: 20828803)
1. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors.
Emons G; Kaufmann M; Gorchev G; Tsekova V; Gründker C; Günthert AR; Hanker LC; Velikova M; Sindermann H; Engel J; Schally AV
Gynecol Oncol; 2010 Dec; 119(3):457-61. PubMed ID: 20828803
[TBL] [Abstract][Full Text] [Related]
2. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
Emons G; Sindermann H; Engel J; Schally AV; Gründker C
Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
[TBL] [Abstract][Full Text] [Related]
3. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
4. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Nagy A; Schally AV
Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
[TBL] [Abstract][Full Text] [Related]
5. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
Engel JB; Schally AV; Buchholz S; Seitz S; Emons G; Ortmann O
Arch Gynecol Obstet; 2012 Aug; 286(2):437-42. PubMed ID: 22555802
[TBL] [Abstract][Full Text] [Related]
6. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
[TBL] [Abstract][Full Text] [Related]
8. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
9. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
Günthert AR; Gründker C; Böttcher B; Emons G
Anticancer Res; 2004; 24(3a):1727-32. PubMed ID: 15274347
[TBL] [Abstract][Full Text] [Related]
10. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
[TBL] [Abstract][Full Text] [Related]
11. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
[TBL] [Abstract][Full Text] [Related]
12. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Nagy A; Schally AV; Emons G
Breast Cancer Res Treat; 2004 Oct; 87(3):255-64. PubMed ID: 15528968
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).
Emons G; Gorchev G; Harter P; Wimberger P; Stähle A; Hanker L; Hilpert F; Beckmann MW; Dall P; Gründker C; Sindermann H; Sehouli J
Int J Gynecol Cancer; 2014 Feb; 24(2):260-5. PubMed ID: 24418927
[TBL] [Abstract][Full Text] [Related]
15. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G
Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
[TBL] [Abstract][Full Text] [Related]
16. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Bajo AM; Schally AV; Halmos G; Nagy A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
Gründker C; Völker P; Griesinger F; Ramaswamy A; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622
[TBL] [Abstract][Full Text] [Related]
18. Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer.
Liu SV; Tsao-Wei DD; Xiong S; Groshen S; Dorff TB; Quinn DI; Tai YC; Engel J; Hawes D; Schally AV; Pinski JK
Clin Cancer Res; 2014 Dec; 20(24):6277-83. PubMed ID: 25278449
[TBL] [Abstract][Full Text] [Related]
19. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
Krebs LJ; Wang X; Pudavar HE; Bergey EJ; Schally AV; Nagy A; Prasad PN; Liebow C
Cancer Res; 2000 Aug; 60(15):4194-9. PubMed ID: 10945629
[TBL] [Abstract][Full Text] [Related]
20. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
Arencibia JM; Bajo AM; Schally AV; Krupa M; Chatzistamou I; Nagy A
Anticancer Drugs; 2002 Oct; 13(9):949-56. PubMed ID: 12394258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
